Merck Sharp & Dohme
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merck Sharp & Dohme sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Merck Sharp & Dohme: 558 sponsored US clinical trials, 120 recruiting.
Merck Sharp & Dohme sponsors 558 registered US clinical trials on ClinicalTrials.gov, 120 of them currently recruiting, and 320 completed. 191 of these trials are in Phase 3-4 (later-stage) and 360 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 25 trials.
Top-decile sponsor footprint
Merck Sharp & Dohme ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
320 of 354 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 5 of 12
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
NCT07548606
A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)
NCT07530289
A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)
NCT07481708
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
NCT07431866
A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)
NCT07222098
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
NCT07199452
A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)
NCT07086079
A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)
NCT07025551
A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)
NCT07334886
A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)
NCT07049939
A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)
NCT07121959
A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)
NCT07063238
A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
NCT07044479
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
NCT06930664
A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)
NCT06942741
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
NCT06860243
A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)
NCT06893081
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
NCT06894771
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
NCT06814132
A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)
NCT06814119
A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
NCT06880874
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
NCT06903715
A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)
NCT06826989
A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)
NCT06818968
A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants
NCT06816043
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
NCT06797674
A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
NCT06719544
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
NCT06633419
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
NCT06643377
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801
A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)
NCT06647628
A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
NCT06609512
A Study of MK-2060 in Healthy Participants (MK-2060-016)
NCT06582602
A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
NCT06597760
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
NCT06586606
Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)
NCT06596668
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
NCT06611033
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
NCT06575595
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
NCT06575959
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
NCT06567002
A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
NCT06575933
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
NCT06482112
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
NCT06609161
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
NCT06554639
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
NCT06450366
A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
NCT06625814
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 230 |
| Phase 2 | 130 |
| Phase 3 | 173 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the Merck Sharp & Dohme pipeline
120 recruiting of 558 indexed (22% open); 320 completed (57%).
Phase mix: 191 late (III/IV) vs 360 early (I/II) (early-phase heavy).
Top condition: Healthy (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merck Sharp & Dohme: open-pipeline peers nationwide
Peers matched on 558 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Merck Sharp & Dohme sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AbbVie · 21% recruiting · 526 trials
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Florida State University · 21% recruiting · 219 trials
- Axsome Therapeutics · 21% recruiting · 28 trials
Related
What to do with this Merck Sharp & Dohme page
558 registered trials is a research-attention snapshot, not an endorsement of Merck Sharp & Dohme or any single study.
- 120 of Merck Sharp & Dohme's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Merck Sharp & Dohme studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merck Sharp & Dohme pipeline card: 558 registered trials from official public datasets.Report a data error.